research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
Search
for
Sort by
Research
120-150 / 1000+ results
research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Successful treatment of severe diffuse alopecia areata with abrocitinib
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research [[Translated article]]RF- Mesotherapy with Bicalutamide: A Novel Alternative for Androgenetic Alopecia
RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
research Comparison of the pharmacoeconomic profiles of treatment regimens for field pattern actinic keratoses
Some blood pressure medications are linked to a higher risk of skin cancer.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists
New compounds were made that are promising for prostate cancer therapy.
research Anticancer drugs in surface waters
Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.
research Cutaneous adverse effects of targeted therapies
Targeted cancer therapies often cause serious skin problems that need careful management.
research Interventions for alopecia areata
Current treatments for alopecia show no significant long-term benefits.
research Eclipta alba extract with potential for hair growth promoting activity
Eclipta alba extract may help hair grow similarly to Minoxidil.
research Interferon in the treatment of cutaneous T-cell lymphoma
Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
research Dermatologic manifestations of endocrine disorders
Skin changes can help diagnose and manage endocrine disorders like thyroid problems, diabetes, and adrenal gland conditions.
research Alopecia Areata Update
Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.
research Alopecia areata: An update
The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.
research Primary cicatricial alopecia
The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.
research Are sex discordant outcomes in COVID-19 related to sex hormones?
Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.
research Avaliação dos efeitos adversos clínicos e alterações laboratoriais em pacientes com acne vulgar tratados com isotretinoína oral
Isotretinoin is safe and effective for acne, with common side effects like dry lips; serious side effects are rare.
research Efficacy of fractional lasers in treating alopecia: a literature review
Fractional lasers seem effective and safe for treating hair loss, but more research is needed to find the best treatment methods.
research Targeted therapy in melanoma
New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
research Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review
Some skin medications can harm male fertility, but they don't seem to cause birth defects from father's exposure.
research New aspects of the treatment of alopecia areata
Personalized treatment plans are important for people with alopecia areata.
research Alopecia Universalis Associated with Cutaneous T Cell Lymphoma
Some patients with a type of skin lymphoma can experience a rare, non-scarring hair loss that looks like another hair loss condition but has distinct features.
research Retinoids for Chemoprophylaxis of Nonmelanoma Skin Cancer
Retinoids can prevent skin cancer in high-risk people but have side effects and require more research on dosing and effectiveness.